Galapagos NV ADR

Yahoo Finance • 13 days ago

Galapagos NV (GLPG)’ CAR-T Therapy Hits 97% Response Rate in Lymphoma Trial

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Galapagos NV is one of them. Galapagos NV (NASDAQ:GLPG) is a Belgian-based firm and is carving out a leading position in next-generation on... Full story

Yahoo Finance • 2 months ago

Galapagos Creates New Subscription Right Plan

Mechelen, Belgium; August 7, 2025, 22.01CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its  Board of Directors created 1,800,000 subscription rights under a new subscription right plan. On August... Full story

Yahoo Finance • 2 months ago

Galapagos creëert nieuw inschrijvingsrechtenplan

Mechelen, België; 7 augustus 2025, 22.01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) kondigt vandaag aan dat haar Raad van Bestuur 1.800.000 inschrijvingsrechten heeft gecreëerd onder een nieuw inschrijvingsre... Full story

Yahoo Finance • 2 months ago

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration (FDA) has granted RMAT designation to GLPG... Full story

Yahoo Finance • 2 months ago

Galapagos NV kondigt aan dat GLPG5101 de status van Regenerative Medicine Advanced Therapy (RMAT) van de FDA krijgt voor de behandeling van recidief/refractair mantelcellymfoom

Mechelen, België; 6 augustus 2025, 7.30 uur CET; gereglementeerde informatie – voorwetenschap – Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag aan dat de Amerikaanse Food and Drug Administration (FDA) de RMAT-status heeft toegeken... Full story

Yahoo Finance • 2 months ago

Get insights into the top gainers and losers of Thursday's pre-market session.

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] GAINERS TICKER CHANGE COMMENT LIDR [https://www.chartmill.com/st... Full story

Yahoo Finance • 3 months ago

CRISPR Therapeutics' SWOT analysis: gene-editing pioneer's stock faces pivotal year

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-editing therapies, stands at a critical juncture as it navigates the complexities of bringing revolutionary treatments to market. The company’s stoc... Full story

Yahoo Finance • 3 months ago

Galapagos Unveils Low-Toxicity CAR-T Data From ATALANTA-1 In Relapsed Non-Hodgkin's Lymphoma

(RTTNews) - Galapagos NV (GLPG), is slated to present new clinical data from its ongoing ATALANTA-1 Phase 1/2 study of GLPG5101 at the 30th European Hematology Association or EHA Congress. The data demonstrate low rates of high-grade toxi... Full story

Yahoo Finance • 5 months ago

Is Galapagos (GLPG) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Galapagos NV (NASDAQ:GLPG) stands against other top healthcare stocks to buy accor... Full story

Yahoo Finance • 7 months ago

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

Galapagos NV Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on accelerating... Full story

Yahoo Finance • 12 months ago

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Galapagos NV Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Director... Full story

Yahoo Finance • 2 years ago

Galapagos signs agreement to transfer Jyseleca® business to Alfasigma

Galapagos NV Transaction expected to close in the first quarter of 2024, subject to customary closing conditions Michele Manto, Galapagos’ Chief Commercial Officer, to join Alfasigma Mechelen, Belgium; 02 January 2024, 07:00 CET; Galapag... Full story

Yahoo Finance • 2 years ago

Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023

Galapagos NV First nine months 2023 key financials: Group revenues of €448.9 million Jyseleca® net sales of €82.1 million Cash and current financial investments of €3.8 billion at 30 September 2023 Full year 2023 net Jyseleca® sales gu... Full story

Yahoo Finance • 3 years ago

Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

Galapagos NV Clear path forward for accelerated growth and value creation Reshape innovation model andbuild fit-for-purpose organizationin key strategic therapeutic areas: immunology and oncology Jyseleca®2022 net sales guidance further... Full story

Yahoo Finance • 3 years ago

Galapagos receives transparency notification from FMR LLC

Galapagos NV Mechelen, Belgium;29 August 2022, 22.01CET;regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a... Full story